Chronobiology Disorders  >>  Hetlioz (tasimelteon)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hetlioz (tasimelteon) / Vanda
NCT01163032 / 2011-000281-35: Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Completed
3
136
US, Europe
tasimelteon, VEC-162, Placebo
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
11/12
11/12
NCT01430754: Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Completed
3
20
US
tasimelteon, VEC-162, Placebo
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
12/12
12/12
NCT01429116 / 2011-004520-35: Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Completed
3
200
US
tasimelteon, VEC-162
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
01/15
01/15

Download Options